Objective: We conducted a prospective naturalistic study of pregnant women with bipolar disorder (BD) to evaluate symptoms of BD across childbearing and assess whether pharmacotherapy reduced their severity.
carries a relative risk of 23 for psychiatric admission for women with BD compared to nonpostpartum women with BD. 10 Few studies have examined the course of BD through pregnancy and after birth. Viguera et al. 11 conducted a prospective observational cohort study to determine the magnitude of risk and time to recurrence for a new episode in 89 women with BD. The overall risk for recurrence in pregnancy was a striking 71%. For women who discontinued vs continued pharmacotherapy, the recurrence risk was twice as high, the median time to recurrence was four times shorter, and the proportion of weeks ill during pregnancy was five times greater. The median recurrence latency was 11 times shorter after abrupt or rapid vs gradual discontinuation of pharmacotherapy. Most recurrences (47%) occurred during the first trimester and the majority were depressive or mixed (74%).
Freeman et al. studied the influence of reproductive events on the course of BD in 50 women. 5 Two-thirds of the women with children had a postpartum mood episode after their first birth, and all of these women had recurrences after subsequent pregnancies. Postpartum episodes were almost exclusively depressive, and increased depressive symptoms in pregnancy were significantly associated with postpartum mood episodes. Wesseloo et al. 12 reported that postpartum relapse rates were significantly higher among those who were medication free during pregnancy (66%) compared to women who used prophylactic medication (23%). Patients with chronic BD were significantly less likely to experience severe episodes postpartum (17%) compared to women with a history of only postpartum psychosis (29%), who have a specific vulnerability to postbirth relapse. In a prospective observational study of pharmacotherapy in 37 women with BD II across childbearing, Sharma et al. 13 reported that the majority of women (54%) did not take psychotropic medication, approximately one-third received monotherapy, and the remainder were treated with combination therapy. During the postpartum period, the majority (86%) of women were treated with psychotropic medication; about one-third received monotherapy, and over half were treated with combination therapy.
While 14% of participants were taking three or more psychotropic drugs during pregnancy, 22% required three or more psychotropic drugs after childbirth in order to manage their symptoms.
The impact of pregnancy on the course of BD across childbearing is an important area of clinical investigation. As the mainstay of treatment is pharmacotherapy, the benefits to the woman and family of BD treatment must be weighed against the risks of drug treatment across childbearing. This decision-making process is a challenging task. Both groups of pregnant women with BD (treated and untreated with pharmacotherapy) have a greater risk for multiple adverse reproductive events (cesarean delivery, preterm birth, and infants with microcephaly, small for gestational age, and with neonatal hypoglycemia) compared to women without BD. 14, 15 Evolving research on the association between adversity during pregnancy (fetal programming) and life-long health has highlighted the risks of uncontrolled disease. 16, 17 To contribute information on the course of BD and the impact of pharmacotherapy on symptom expression across childbearing, we conducted a prospective study of a community cohort of pregnant women with BD. We characterized symptoms of depression and mania throughout pregnancy and the first year after birth and compared symptom levels of psychotropic-treated women to those of nonpsychotropic-treated women. Our hypothesis was that psychotropic-treated women would have less symptom burden and functional impairment across childbearing compared to women who were not receiving pharmacotherapy. tested positive by urine screen for a nonprescription, illicit drug at intake were not eligible for the study; however, we enrolled women who tested positive for cannabis because its use was so frequent that excluding them would have limited both the sample accrual and generalizability.
| METHODS

| Subjects
All subjects received consultation regarding the management of BD, and a summary of the recommendations was sent to participants and community prescribers. Decisions about treatment were made by participants and community healthcare professionals. The choice to accept or decline treatment or to implement investigators' clinical recommendations did not dictate study inclusion or retention.
| Assessments
Maternal assessments were scheduled at 20, 30, and 36 weeks' gestation and 2, 12, 26, and 52 weeks postpartum. Evaluations were held in our specialized women's mental health center, conducted at the participants' homes or by telephone to minimize barriers in collecting data. In addition to establishing the diagnosis of BD, the SCID was administered to determine comorbid and lifetime diagnoses. At all study visits, subjects were interviewed about tobacco, illicit substance, and alcohol use. Symptom severity was assessed using the 29-item Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS), which contains the familiar 17-item Hamilton Rating Scale for Depression (HAM-D-17).
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The SIGH-ADS also captures eight atypical symptoms of depression, which are more common in women 20 and individuals with BD. 
| Statistical methods/data analysis
| RESULTS
A total of 159 pregnant women with BD were enrolled ( Figure 1 ).
Seven participants were lost to follow-up during pregnancy (N=152)
and an additional 45 were lost to follow-up during the postpartum period (N=107). A total of 88 women (58% of women with BD) were exposed to medication during pregnancy; however, about a quarter of these women discontinued their treatment in the first trimester (Stop T1) and the remainder continued pharmacotherapy into the second and third trimesters (OnT2/T3). There were 64 women (42%) who were not exposed to psychotropic medication (No Psych Med) during pregnancy. About three-quarters (n=78, 73%) of the women were treated with psychotropic agents (Psych Med) after birth. The demographics of the subjects, for the overall diverse sample and divided by exposure group in pregnancy and postpartum, are displayed in A total of 88 (58%) pregnant women were treated with psychotropic agents; however, substantial changes in both the class of drug prescribed and the individuals treated were observed across pregnancy (Table 2) (Table 3) . No statistically significant differences in the mixed-effect models were observed for comparison of depression symptom levels among the three groups. During the postpartum period ( Data presented as mean ± standard deviation SD and n (%). NOS, not otherwise specified; No Psych Med, nonpsychotropic-treated women; Stop T1, women who took psychotropic agents only during the first trimester of pregnancy; OnT2/T3, women who continued medication throughout pregnancy or had exposure only during Trimester 2 and 3.
a Presented as use at any point in pregnancy (or postpartum) by an individual woman.
T A B L E 1 (Continued)
T A B L E 2 Medication use by women by trimester of pregnancy and postpartum Guideline-concordant pharmacotherapy is highlighted in green. Med, medication; PP, postpartum a N is the number of women providing data at the assessment point. Note that the N for "at any time" during pregnancy or postpartum refers to individual subjects, but the denominator for calculated percentages is higher due to changes in medications prescribed in the same patient at varying points in pregnancy or postpartum (denominator =113 in pregnancy and 104 postpartum).
[Colour table can be viewed at wileyonlinelibrary.com] the four assessments tended to be lower than those observed during pregnancy for both the psychotropic-treated and untreated groups.
Similar to pregnancy, no significant differences in the mixed models were observed in psychotropic treated vs untreated women.
On the MRS, the majority of pregnant women scored a zero, and the proportion of women who had a nonzero score did not differ significantly among the three groups. After birth, the proportion of women endorsing any symptoms on the MRS did not differ significantly between psychotropic-treated and untreated subjects.
Surprisingly, no substantial elevation in manic or depression symptom scores was observed in the immediate postbirth period at week 2.
Among the functional measures for pregnant women, the only significant difference was for the SF-12-MS scores; however, the group difference was no longer significant when we adjusted for mul- During pregnancy, the mean GAS scores (59.9-65.8) were generally in the 61st to 70th decile both for treated and untreated women. This decile is described as "some mild symptoms or some difficulty in social, occupational, or school functioning, but generally functioning pretty well, and has some meaningful interpersonal relationships". 25 After birth, for both psychotropic-treated and untreated women, the mean GAS scores 
| DISCUSSION
In the present observational study of a community sample of women with BD, slightly more than half received psychotropic drugs during uncertainty about pharmacotherapy on the part of healthcare providers, policy makers, and patients. 28 The application of guidelines for BD to pregnant and breastfeeding women presents additional challenges, and reviews are available. 14, 29 Our data are consistent with previous studies of perinatal women, in that depression was the predominant manifestation of BD both during pregnancy and after birth. 10, 11, 30 Depression is strongly associated with perceived poor quality of life, 31 and our subjects consistently reported problems with functioning. Comorbid psychiatric disorders are also associated with lower scores on functional measures in patients with BD. 32 Consistent with epidemiological and clinical studies of BD, our sample also had a high rate of lifetime comorbid anxiety disorders (about 50%). [33] [34] [35] For these patients, the course of BD is likely to be more severe, with shorter periods in euthymia, more rapid time to relapse, slower time to remission, and poorer functioning and quality of life. 34, 36 This comorbidity and the resulting effects on illness course contribute to chronic symptoms and the negative impact on parenting.
14 The rates of self-reported smoking, alcohol, and illicit drug use during pregnancy in our subjects are similar to those in a study demonstrating that perinatal women with BD have more substance use compared to perinatal women with psychiatric diagnoses other than BD.
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Even with the exclusion of alcohol-and substance-dependent women at intake by urine drug screen and focused interview, the women with BD who were enrolled in the study smoked (40%), drank alcohol (19%), and used illicit drugs, particularly cannabis (27%), at some point during pregnancy. Substance use comorbidity contributes to poor response to treatment. Providing targeted substance use education and intervention is an opportunity to improve pregnancy outcomes in women with BD, 38 and collaborative care treatment models that integrate mental health and pregnancy care also enhance outcomes.
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We did not confirm our hypothesis that women who received psychotropic medication would have less symptom burden and functional impairment compared to women In the No Psych Med group.
Depression and mania scores were relatively constant across pregnancy and the postpartum period in all groups. We propose several explanations for these results. About a third of women were treated with medications without established efficacy for BD. Additionally, maintaining therapeutic doses of psychotropic drugs is challenging due to the changing physiological milieu of pregnancy and the induction of cytochrome P 450 enzymes, which reduce plasma drug concentrations.
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We did not observe a substantial increase in either depressive or manic symptoms in the postpartum period, which contrasts with our expectations based upon epidemiological studies. Our subjects experienced lower levels of depressive and manic symptoms after birth than during pregnancy, in contrast to studies which suggest that pregnancy is a low-risk period for recurrence of BD. 3, 42, 43 However, our data corroborate the findings of investigators who report that women with chronic BD are at risk for a worsening of mood symptoms during pregnancy. 5, 11 Consistent with our results, Bergink et al. 44 reported that women with chronic BD (as in our sample), compared to women with a history of acute postpartum episodes only, had a similar rate of relapse during pregnancy (24%) as postpartum (22%), regardless of lithium treatment. The symptom course of our subjects improved on all measures after birth, and the majority resumed psychotropic medication in the postpartum period. Another explanation is that about two-thirds of the treated women were taking an antimanic agent, most often antipsychotic drugs, in the third trimester, which may have reduced the risk of postbirth mania.
The strengths of the present investigation include multiple observations of a difficult-to-study population-women with chronic BD who are coping with pregnancy and childbirth. The diversity in this community sample of women being treated and/or monitored for BD enhances the generalizability of results; however, the subjects were able to provide informed consent, meet eligibility criteria, and participate in follow-up assessments, which suggests that women who did not participate may have had more severe disorders. Despite intense effort by the study team, another limitation was that the follow-up rate postdelivery was only 70%; therefore, it is possible that worsening of illness and inability to be reached for follow-up accounted for postpartum attrition.
The treatment of pregnant and postpartum women with BD is a clinical challenge, as elegantly described by Burt et al. 45 The mental health of the mother is a priority in optimizing pregnancy outcomes, and the risks of poorly controlled disease must be balanced against 
